- FOURTH QUARTER REVENUE OF $129.2
MILLION, DOWN 4% SEQUENTIALLY AND UP SLIGHTLY
YEAR-OVER-YEAR
- FOURTH QUARTER OPERATING INCOME OF $14.2 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 14% SEQUENTIALLY, UP 4%
YEAR-OVER-YEAR
- FOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF
12%
- FOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.22, DOWN 12% SEQUENTIALLY, UP 16%
YEAR-OVER-YEAR
- FOURTH QUARTER FREE CASH FLOW OF $16.2 MILLION, UP OVER 50%
SEQUENTIALLY
- DEBT LEVERAGE RATIO REDUCED TO 1.31, AND NET DEBT REDUCED BY
$11.7 MILLION
- COMPANY REPURCHASED 264,982 SHARES OF COMMON STOCK, A VALUE
OF $4.9 MILLION, DURING THE FOURTH
QUARTER
- COMPANY ANNOUNCES Q1 2025 QUARTERLY DIVIDEND
- FULL YEAR REVENUE OF $523.8
MILLION, UP 3%
- FULL YEAR OPERATING INCOME OF $58.6
MILLION; EX-ITEMS, $65.3
MILLION, UP 7%
- FULL YEAR GAAP EPS OF $0.66;
EX-ITEMS, EPS OF $0.87, UP
9%
- FULL YEAR FREE CASH FLOW OF $43.4
MILLION, UP OVER 200% COMPARED TO 2023
HOUSTON, Jan. 29,
2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE:
"CLB") ("Core", "Core Lab", or the "Company") reported fourth
quarter 2024 revenue of $129,200,000.
Core's operating income was $14,200,000, with diluted earnings per share
("EPS") of $0.15, all in
accordance with U.S. generally accepted accounting principles
("GAAP"). Operating income, ex-items, a non-GAAP financial measure,
was $15,700,000, yielding operating
margins of 12%, and EPS, ex-items, of $0.22. For the full year 2024, revenue of
$523,800,000 was up 3% compared to
2023, generating operating income, ex-items, of $65,300,000 with incremental margins of 29%. The
Company's full year EPS, ex-items, was $0.87, representing year-over-year growth of 9%.
A full reconciliation of non-GAAP financial measures is included in
the attached financial tables.

Core's CEO, Larry Bruno stated,
"Our full year financial results delivered improvements in revenue,
operating income, operating margins, free cash flow and earnings
per share. Our performance was driven by resilient demand for our
Reservoir Description services which continued to grow across our
international laboratory network despite headwinds from reduced
U.S. land activity and disruptions caused by on-going geopolitical
conflicts and associated sanctions. Core's investments to expand
capabilities in the Middle East
are now yielding returns. While Production Enhancement experienced
higher international product sales and increased demand for Core's
completion diagnostic services, full year financial performance was
adversely impacted by lower levels of onshore well completions in
the U.S. compared to 2023. The Company also continued to strengthen
its balance sheet by reducing debt. As of December 31, 2024, our debt leverage ratio was
reduced to 1.31, the lowest it has been in over eight years. Core
remains focused on executing its strategic business priorities
which include further reduction of debt and strengthening the
balance sheet. In addition, we will remain active in pursuit of
growth opportunities and maintain our long-standing practice of
returning excess free cash to our shareholders, as we did in the
fourth quarter through a combination of share buybacks and our
quarterly dividend."
Reservoir Description
Reservoir Description operations are closely correlated with
trends in international and offshore activity levels, with
approximately 80% of revenue sourced from projects originating
outside the U.S. Revenue in the fourth quarter of 2024 was
$86,800,000, down 2% sequentially,
however, up 3% from last year. Operating income on a GAAP basis was
$16,600,000, while operating income,
ex-items, was $14,100,000, yielding
operating margins over 16%, expanding 170 basis points,
year-over-year. The segment's financial performance in the fourth
quarter was adversely impacted by a sequential decline in U.S. land
activity, as well as on-going international geopolitical conflicts
and associated sanctions. These factors were somewhat offset by
continued growth in demand for reservoir rock and fluid analysis in
several international regions. For the full year 2024, the
segment's revenue of $346,100,000
increased 4%, generating operating income, ex-items, of
$52,800,000 with incremental margins
over 58%.
In the fourth quarter of 2024, Core Lab completed a laboratory
study for a Middle Eastern National Oil Company ("NOC") that
utilized Core's proprietary Nuclear Magnetic Resonance ("NMR")
technologies. The study combined 2D High Frequency and Low
Frequency NMR instrumentation to investigate the reservoir rocks at
varying temperatures. By utilizing multiple NMR frequencies and
other proprietary technologies, Core's scientists were able to
differentiate liquid (potentially movable) from solid (immovable)
hydrocarbon phases in the rock samples. This critical distinction
is often very difficult to determine from traditional down-hole log
analysis techniques. Without the analytical results and
interpretations provided by Core Lab, the NOC might have
overestimated recoverable reserves in the target stratigraphic
horizon.
Production Enhancement
Production Enhancement operations, which are focused on complex
completions in unconventional oil and gas reservoirs in the U.S.,
as well as conventional and unconventional projects across the
globe, posted fourth quarter 2024 revenue of $42,400,000, down 7% sequentially and 3%
year-over-year. Operating loss on a GAAP basis was $(2,600,000), while operating income, ex-items,
was $1,500,000, yielding operating
margins of 4%. The sequential and year-over-year decline in revenue
reflects lower U.S. onshore completion activity which resulted in a
decline in product sales. However, improved demand for completion
diagnostic services and international product sales somewhat offset
the soft U.S. onshore market. For the full year 2024, the segment's
revenue of $177,700,000 was
comparable to full year 2023, despite the decrease in U.S. onshore
well completion activity.
In the fourth quarter of 2024, Core Lab collaborated with a
leading oilfield services company operating in Southeast Asia to improve productivity from a
low permeability gas reservoir. The Company's Production
Enhancement team deployed the Company's proprietary
STIMGUNTM propellant technology to improve hydrocarbon
flow from the reservoir. Core's approach combined conventional
perforating energetics with even higher energy STIMGUNTM
propellant stimulation to achieve improved near-well bore
permeability. When activated, STIMGUNTM releases an
engineered, sequenced, and controlled burst of energy that creates
fracture networks inside the rock formation, adjacent to the
perforation tunnels. This international project, which employed
more than 1,200 feet of STIMGUNTM, resulted in a 55%
increase in expected natural gas production, highlighting the
exceptional performance of Core's proprietary completion
technology.
Also in the fourth quarter of 2024, Core Lab was engaged by an
operator in Canada to determine
oil flow from conventional wells where a single vertical borehole
had multiple horizontal legs. The operator wanted to identify
which legs were contributing oil production to the vertical
borehole. By placing unique, engineered, solid particle
FlowProfiler™ oil tracers into each horizontal leg, the operator
was able to confirm oil production from 87% of the traced legs
after thirty days of flow. As an enhancement to this service,
Core Lab has recently introduced FlowProfiler™ water tracers, which
will allow operators to determine both water and oil production
from each of the horizontal legs.
Liquidity, Free Cash Flow, Share Repurchases, and
Dividend
Core continues to focus on maximizing free cash flow ("FCF"), a
non-GAAP financial measure defined as cash from operations less
capital expenditures. For the fourth quarter of 2024, cash from
operations was $20,600,000 and
capital expenditures were $4,400,000,
yielding FCF of $16,200,000. The
Company generated $43,400,000 of FCF
for the twelve months ending December 31,
2024, an improvement of over 200% compared to full year
2023. The year-over-year improvement in FCF reflects higher
profitability, as well as better management of inventory and
working capital.
In the fourth quarter, Core Lab used a portion of this FCF to
repurchase 264,982 shares at an aggregate purchase price of
$4,900,000.
As of December 31, 2024, Core's
net debt (defined as long-term debt less cash and cash equivalents)
was $108,800,000, which was reduced
by $11,700,000 during the quarter and
by $42,000,000 for the full year. The
Company's leverage ratio (calculated as total net debt divided by
adjusted EBITDA for the last four quarters) was reduced to 1.31 as
of December 31, 2024, which improved from 1.47 as of
September 30, 2024.
Core expects to continue generating positive FCF in future
quarters. The Company will remain focused on executing its
strategic business initiatives while also further reducing its
leverage ratio. In addition, Core Lab will continue to evaluate
allocation of capital and other uses of free cash.
On October 23, 2024, Core's Board
of Directors ("Board") announced a quarterly cash dividend of
$0.01 per share of common stock,
which was paid on November 25, 2024,
to shareholders of record on November 4,
2024.
On January 29, 2025, the Board
approved a cash dividend of $0.01 per
share of common stock payable on March 3, 2025, to
shareholders of record on February
10, 2025.
Return On Invested Capital
The Board and the Company's Executive Management continue to
focus on strategies that maximize return on invested capital
("ROIC") and FCF, factors that have high correlation to total
shareholder return. Core's commitment to an asset-light business
model and disciplined capital stewardship promote capital
efficiency and are designed to produce more predictable and
superior long-term ROIC.
The Board has established an internal metric to demonstrate ROIC
performance relative to the oilfield service companies listed as
Core's Comp Group by Bloomberg, as the Company continues to believe
superior ROIC will result in higher total shareholder return. Using
Bloomberg's formula, the Company's ROIC for the fourth quarter of
2024 improved to 10.3%.
Industry and Core Lab Outlook and Guidance
As 2025 unfolds, Core will continue to execute its strategic
plan of technology investments targeted to both solve client
problems and capitalize on Core's growth opportunities. A cautious
near-term approach was adopted by operators in the back half of
2024, driven by concerns over a potential imbalance between crude
oil supply and demand. However, Core maintains its constructive
long-term outlook on international upstream projects for 2025 and
beyond. The IEA, EIA and OPEC+ continue to forecast growth in crude
oil demand between approximately 1.1 and 1.4 million barrels per
day for 2025, which is in addition to the natural decline of
production from existing fields. As such, continued investment
in the development of onshore and offshore crude oil fields will be
required to meet demand.
In the near term, the Company expects that crude oil markets
will remain volatile due to global economic uncertainties and
geopolitical risks. In January of 2025, expanded sanctions 1)
impacted the maritime movement and trading of crude oil and derived
products, along with the demand for necessary laboratory assay
work, and 2) prohibited product sales and services to a broader
group of entities.
In alignment with this outlook, Core will remain well-engaged on
long-cycle international projects. Looking ahead, as international
project activity is expected to be steady, committed long-term
upstream projects from the South Atlantic Margin, North and
West Africa, Norway, the Middle East, and certain
areas of Asia Pacific support
mid-single digit year-over-year growth in demand for Core Lab's
services and products. In the U.S., onshore activity is projected
to be flat to slightly down compared to 2024.
In addition to the geopolitical risks and recently expanded
sanctions, Core expects typical sequential seasonal industry
patterns will cause activity in the first quarter of 2025 to
decline in some regions. Severe weather in the U.S. and
Mediterranean regions resulted in suspended client activities and
facility closures. As such, Core projects Reservoir Description's
first quarter revenue to range from $82,000,000 to $85,000,000, with operating income of
$9,000,000 to $10,700,000. For the first quarter 2025,
onshore U.S. drilling and completion activity was adversely
impacted by freezing conditions and continued to decline throughout
January; however, activity is expected to improve as the quarter
unfolds. Consequently, Production Enhancement's first quarter
revenue is expected to range from $39,000,000 to $42,000,000, with operating income of
$1,100,000 to $2,000,000.
The Company's first quarter 2025 revenue is projected to range
from $121,000,000 to $127,000,000, with operating income of
$10,200,000 to $12,800,000, yielding operating margins of
approximately 9%. Core's effective tax is projected at
approximately 25% for 2025. This change in the effective tax rate
is projected to increase income tax expense for the first quarter
of 2025 by approximately $500,000. As
such, EPS for the first quarter of 2025 is expected to be
$0.12 to $0.16.
The Company's first quarter 2025 guidance is based on
projections for underlying operations and excludes gains and losses
in foreign exchange.
Earnings Call Scheduled
The Company has scheduled a conference call to discuss Core's
fourth quarter and full year 2024 earnings announcement. The call
will begin at 7:30 a.m. CDT / 8:30
a.m. EDT on Thursday, January 30,
2025. To register for the listen-only webcast, log on to
www.corelab.com 15 minutes before the start of the call. For those
not available to listen to the live webcast, a replay and
transcript will be available on the Company's website shortly after
the call. Analysts may contact jenna.palfrey@corelab.com for
conference call dial-in information.
Core Laboratories Inc. is a leading provider of proprietary and
patented reservoir description and production enhancement services
and products used to optimize petroleum reservoir performance. The
Company has over 70 offices in more than 50 countries and is
located in every major oil-producing province in the world. This
release, as well as other statements we make, includes
forward-looking statements regarding the Company's future revenue,
profitability, business strategies and developments, demand for the
Company's products and services and for products and services of
the oil and gas industry generally, made in reliance upon the safe
harbor provisions of Federal securities law. The Company's outlook
is subject to various important cautionary factors, including risks
and uncertainties related to the oil and natural gas industry,
business and general economic conditions, including inflationary
pressures, the ability to achieve the benefits of the
redomestication of the parent company from the Netherlands to the United States, international markets,
international political climates, including the Russia-Ukraine and the Middle East geopolitical conflicts, public
health crises, and any related actions taken by businesses and
governments, and other factors as more fully described in the
Company's most recent Forms 10-K, 10-Q and 8-K filed with or
furnished to the U.S. Securities and Exchange Commission. These
important factors could cause the Company's actual results to
differ materially from those described in these forward-looking
statements. Such statements are based on current expectations of
the Company's performance and are subject to a variety of factors,
some of which are not under the control of the Company. Because the
information herein is based solely on data currently available, and
because it is subject to change as a result of changes in
conditions over which the Company has no control or influence, such
forward-looking statements should not be viewed as assurance
regarding the Company's future performance.
The Company undertakes no obligation to publicly update or
revise any forward-looking statement to reflect events or
circumstances that may arise after the date of this press release,
except as required by law.
Visit the Company's website at www.corelab.com.
CORE LABORATORIES
INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS (In thousands, except per share data)
(Unaudited)
|
|
|
|
Quarter
Ended
|
|
|
%
Variance
|
|
|
December 31,
2024
|
|
|
September 30,
2024
|
|
|
December 31,
2023
|
|
|
vs.
Q3-2024
|
|
vs.
Q4-2023
|
REVENUE
|
|
$
|
129,237
|
|
|
$
|
134,397
|
|
|
$
|
128,210
|
|
|
(3.8) %
|
|
0.8 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING
EXPENSES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs of services and
product sales
|
|
|
106,199
|
|
|
|
106,805
|
|
|
|
101,517
|
|
|
(0.6) %
|
|
4.6 %
|
General and
administrative expense
|
|
|
9,080
|
|
|
|
8,642
|
|
|
|
8,665
|
|
|
5.1 %
|
|
4.8 %
|
Depreciation and
amortization
|
|
|
3,664
|
|
|
|
3,676
|
|
|
|
3,874
|
|
|
(0.3) %
|
|
(5.4) %
|
Other (income) expense,
net
|
|
|
(3,880)
|
|
|
|
(4,529)
|
|
|
|
(427)
|
|
|
NM
|
|
NM
|
Total operating
expenses
|
|
|
115,063
|
|
|
|
114,594
|
|
|
|
113,629
|
|
|
0.4 %
|
|
1.3 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING
INCOME
|
|
|
14,174
|
|
|
|
19,803
|
|
|
|
14,581
|
|
|
(28.4) %
|
|
(2.8) %
|
Interest
expense
|
|
|
2,629
|
|
|
|
3,108
|
|
|
|
3,618
|
|
|
(15.4) %
|
|
(27.3) %
|
Income before income
taxes
|
|
|
11,545
|
|
|
|
16,695
|
|
|
|
10,963
|
|
|
(30.8) %
|
|
5.3 %
|
Income tax
expense
|
|
|
4,076
|
|
|
|
4,691
|
|
|
|
8,529
|
|
|
(13.1) %
|
|
(52.2) %
|
Net income
|
|
|
7,469
|
|
|
|
12,004
|
|
|
|
2,434
|
|
|
(37.8) %
|
|
206.9 %
|
Net income attributable
to non-
controlling interest
|
|
|
66
|
|
|
|
259
|
|
|
|
235
|
|
|
NM
|
|
NM
|
Net income attributable
to Core
Laboratories Inc.
|
|
$
|
7,403
|
|
|
$
|
11,745
|
|
|
$
|
2,199
|
|
|
(37.0) %
|
|
236.7 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per
share
|
|
$
|
0.16
|
|
|
$
|
0.25
|
|
|
$
|
0.05
|
|
|
(36.0) %
|
|
220.0 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per
share
attributable to Core Laboratories
Inc.
|
|
$
|
0.15
|
|
|
$
|
0.25
|
|
|
$
|
0.05
|
|
|
(40.0) %
|
|
200.0 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted weighted
average common
shares outstanding
|
|
|
47,773
|
|
|
|
47,820
|
|
|
|
47,557
|
|
|
(0.1) %
|
|
0.5 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
|
|
35
|
%
|
|
|
28
|
%
|
|
|
78
|
%
|
|
NM
|
|
NM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SEGMENT
INFORMATION:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reservoir
Description
|
|
$
|
86,793
|
|
|
$
|
88,840
|
|
|
$
|
84,628
|
|
|
(2.3) %
|
|
2.6 %
|
Production
Enhancement
|
|
|
42,444
|
|
|
|
45,557
|
|
|
|
43,582
|
|
|
(6.8) %
|
|
(2.6) %
|
Total
|
|
$
|
129,237
|
|
|
$
|
134,397
|
|
|
$
|
128,210
|
|
|
(3.8) %
|
|
0.8 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reservoir
Description
|
|
$
|
16,643
|
|
|
$
|
16,487
|
|
|
$
|
12,259
|
|
|
0.9 %
|
|
35.8 %
|
Production
Enhancement
|
|
|
(2,597)
|
|
|
|
3,232
|
|
|
|
2,195
|
|
|
(180.4) %
|
|
(218.3) %
|
Corporate and
Other
|
|
|
128
|
|
|
|
84
|
|
|
|
127
|
|
|
NM
|
|
NM
|
Total
|
|
$
|
14,174
|
|
|
$
|
19,803
|
|
|
$
|
14,581
|
|
|
(28.4) %
|
|
(2.8) %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
"NM" means not
meaningful
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CORE LABORATORIES
INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS (In thousands, except per share data)
(Unaudited)
|
|
|
|
Year Ended December
31,
|
|
|
%
Variance
|
|
|
2024
|
|
|
2023
|
|
|
|
REVENUE
|
|
$
|
523,848
|
|
|
$
|
509,790
|
|
|
2.8 %
|
|
|
|
|
|
|
|
|
|
OPERATING
EXPENSES:
|
|
|
|
|
|
|
|
|
Costs of services and
product sales
|
|
|
420,522
|
|
|
|
399,957
|
|
|
5.1 %
|
General and
administrative expense
|
|
|
39,770
|
|
|
|
40,259
|
|
|
(1.2) %
|
Depreciation and
amortization
|
|
|
14,953
|
|
|
|
15,784
|
|
|
(5.3) %
|
Other (income) expense,
net
|
|
|
(9,953)
|
|
|
|
(850)
|
|
|
NM
|
Total operating
expenses
|
|
|
465,292
|
|
|
|
455,150
|
|
|
2.2 %
|
|
|
|
|
|
|
|
|
|
OPERATING
INCOME
|
|
|
58,556
|
|
|
|
54,640
|
|
|
7.2 %
|
Interest
expense
|
|
|
12,369
|
|
|
|
13,430
|
|
|
(7.9) %
|
Income before income
taxes
|
|
|
46,187
|
|
|
|
41,210
|
|
|
12.1 %
|
Income tax
expense
|
|
|
14,034
|
|
|
|
4,185
|
|
|
235.3 %
|
Net income
|
|
|
32,153
|
|
|
|
37,025
|
|
|
(13.2) %
|
Net income attributable
to non-controlling interest
|
|
|
753
|
|
|
|
350
|
|
|
NM
|
Net income attributable
to Core Laboratories Inc.
|
|
$
|
31,400
|
|
|
$
|
36,675
|
|
|
(14.4) %
|
|
|
|
|
|
|
|
|
|
Diluted earnings per
share
|
|
$
|
0.67
|
|
|
$
|
0.78
|
|
|
(14.1) %
|
|
|
|
|
|
|
|
|
|
Diluted earnings per
share attributable to Core Laboratories Inc.
|
|
$
|
0.66
|
|
|
$
|
0.77
|
|
|
(14.3) %
|
|
|
|
|
|
|
|
|
|
Diluted weighted
average common shares outstanding
|
|
|
47,685
|
|
|
|
47,523
|
|
|
0.3 %
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
|
|
30
|
%
|
|
|
10
|
%
|
|
NM
|
|
|
|
|
|
|
|
|
|
SEGMENT
INFORMATION:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
Reservoir
Description
|
|
$
|
346,146
|
|
|
$
|
333,345
|
|
|
3.8 %
|
Production
Enhancement
|
|
|
177,702
|
|
|
|
176,445
|
|
|
0.7 %
|
Total
|
|
$
|
523,848
|
|
|
$
|
509,790
|
|
|
2.8 %
|
|
|
|
|
|
|
|
|
|
Operating
income:
|
|
|
|
|
|
|
|
|
Reservoir
Description
|
|
$
|
51,466
|
|
|
$
|
41,039
|
|
|
25.4 %
|
Production
Enhancement
|
|
|
6,612
|
|
|
|
12,519
|
|
|
(47.2) %
|
Corporate and
Other
|
|
|
478
|
|
|
|
1,082
|
|
|
(55.8) %
|
Total
|
|
$
|
58,556
|
|
|
$
|
54,640
|
|
|
7.2 %
|
|
|
|
|
|
|
|
|
|
"NM" means not
meaningful
|
|
|
|
|
|
|
|
|
CORE LABORATORIES
INC. & SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE
SHEETS (In thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
%
Variance
|
ASSETS:
|
|
December 31,
2024
|
|
|
September 30,
2024
|
|
|
December 31,
2023
|
|
|
vs.
Q3-2024
|
|
vs.
Q4-2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
19,157
|
|
|
$
|
21,474
|
|
|
$
|
15,120
|
|
|
(10.8) %
|
|
26.7 %
|
Accounts receivable,
net
|
|
|
111,761
|
|
|
|
117,591
|
|
|
|
109,352
|
|
|
(5.0) %
|
|
2.2 %
|
Inventories
|
|
|
59,402
|
|
|
|
65,490
|
|
|
|
71,702
|
|
|
(9.3) %
|
|
(17.2) %
|
Other current
assets
|
|
|
36,286
|
|
|
|
30,672
|
|
|
|
26,962
|
|
|
18.3 %
|
|
34.6 %
|
Total current
assets
|
|
|
226,606
|
|
|
|
235,227
|
|
|
|
223,136
|
|
|
(3.7) %
|
|
1.6 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property, plant and
equipment, net
|
|
|
97,063
|
|
|
|
97,606
|
|
|
|
99,626
|
|
|
(0.6) %
|
|
(2.6) %
|
Right of use
assets
|
|
|
56,488
|
|
|
|
56,650
|
|
|
|
53,842
|
|
|
(0.3) %
|
|
4.9 %
|
Intangibles, goodwill
and other long-
term assets, net
|
|
|
210,249
|
|
|
|
210,983
|
|
|
|
209,791
|
|
|
(0.3) %
|
|
0.2 %
|
Total assets
|
|
$
|
590,406
|
|
|
$
|
600,466
|
|
|
$
|
586,395
|
|
|
(1.7) %
|
|
0.7 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
EQUITY:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
34,549
|
|
|
$
|
33,627
|
|
|
$
|
33,506
|
|
|
2.7 %
|
|
3.1 %
|
Operating lease
liabilities
|
|
|
10,690
|
|
|
|
11,435
|
|
|
|
10,175
|
|
|
(6.5) %
|
|
5.1 %
|
Other current
liabilities
|
|
|
52,347
|
|
|
|
49,876
|
|
|
|
44,416
|
|
|
5.0 %
|
|
17.9 %
|
Total current
liabilities
|
|
|
97,586
|
|
|
|
94,938
|
|
|
|
88,097
|
|
|
2.8 %
|
|
10.8 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt,
net
|
|
|
126,111
|
|
|
|
139,872
|
|
|
|
163,134
|
|
|
(9.8) %
|
|
(22.7) %
|
Long-term operating
lease liabilities
|
|
|
43,343
|
|
|
|
43,727
|
|
|
|
42,076
|
|
|
(0.9) %
|
|
3.0 %
|
Other long-term
liabilities
|
|
|
65,629
|
|
|
|
65,508
|
|
|
|
63,281
|
|
|
0.2 %
|
|
3.7 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total equity
|
|
|
257,737
|
|
|
|
256,421
|
|
|
|
229,807
|
|
|
0.5 %
|
|
12.2 %
|
Total liabilities and
equity
|
|
$
|
590,406
|
|
|
$
|
600,466
|
|
|
$
|
586,395
|
|
|
(1.7) %
|
|
0.7 %
|
CORE LABORATORIES
INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS (In thousands)
(Unaudited)
|
|
|
|
Year Ended December
31,
|
|
|
|
2024
|
|
|
2023
|
|
CASH FLOWS FROM
OPERATING ACTIVITIES:
|
|
|
|
|
|
|
Net income
|
|
$
|
32,153
|
|
|
$
|
37,025
|
|
Adjustments to
reconcile net income to net cash provided by operating
activities:
|
|
|
|
|
|
|
Stock-based
compensation
|
|
|
3,755
|
|
|
|
13,971
|
|
Depreciation and
amortization
|
|
|
14,953
|
|
|
|
15,784
|
|
Deferred income
taxes
|
|
|
674
|
|
|
|
(10,811)
|
|
Accounts
receivable
|
|
|
(3,612)
|
|
|
|
(2,618)
|
|
Inventories
|
|
|
9,367
|
|
|
|
(12,976)
|
|
Accounts
payable
|
|
|
519
|
|
|
|
(12,878)
|
|
Other adjustments to
net income
|
|
|
(1,421)
|
|
|
|
(2,708)
|
|
Net cash provided by
operating activities
|
|
|
56,388
|
|
|
|
24,789
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM
INVESTING ACTIVITIES:
|
|
|
|
|
|
|
Capital
expenditures
|
|
|
(13,028)
|
|
|
|
(10,579)
|
|
Net proceeds from life
insurance policies and from insurance recovery
|
|
|
4,878
|
|
|
|
3,375
|
|
Other investing
activities
|
|
|
1,756
|
|
|
|
552
|
|
Net cash used in
investing activities
|
|
|
(6,394)
|
|
|
|
(6,652)
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM
FINANCING ACTIVITIES:
|
|
|
|
|
|
|
Repayment of long-term
debt
|
|
|
(82,000)
|
|
|
|
(211,000)
|
|
Proceeds from long-term
debt
|
|
|
44,000
|
|
|
|
202,000
|
|
Equity related
transaction costs
|
|
|
(756)
|
|
|
|
(4,068)
|
|
Dividends
paid
|
|
|
(1,876)
|
|
|
|
(1,868)
|
|
Repurchase of common
stock
|
|
|
(5,306)
|
|
|
|
(2,202)
|
|
Other financing
activities
|
|
|
(19)
|
|
|
|
(1,307)
|
|
Net cash used in
financing activities
|
|
|
(45,957)
|
|
|
|
(18,445)
|
|
|
|
|
|
|
|
|
NET CHANGE IN CASH AND
CASH EQUIVALENTS
|
|
|
4,037
|
|
|
|
(308)
|
|
CASH AND CASH
EQUIVALENTS, beginning of year
|
|
|
15,120
|
|
|
|
15,428
|
|
CASH AND CASH
EQUIVALENTS, end of year
|
|
$
|
19,157
|
|
|
$
|
15,120
|
|
Non-GAAP Information
Management believes that the exclusion of certain income and
expenses enables it to evaluate more effectively the Company's
operations period-over-period and to identify operating trends that
could otherwise be masked by the excluded Items. For this reason,
management uses certain non-GAAP measures that exclude these Items
and believes that this presentation provides a clearer comparison
with the results reported in prior periods. The non-GAAP financial
measures should be considered in addition to, and not as a
substitute for, the financial results prepared in accordance with
GAAP, as more fully discussed in the Company's financial statements
and filings with the Securities and Exchange Commission.
Reconciliation of
Operating Income, Net Income and Diluted Earnings Per Share
Attributable to
Core Laboratories Inc.
|
(In thousands, except
per share data)
|
(Unaudited)
|
|
|
|
Operating
Income
|
|
|
|
Quarter
Ended
|
|
|
|
December 31,
2024
|
|
|
September 30,
2024
|
|
|
December 31,
2023
|
|
GAAP
reported
|
|
$
|
14,174
|
|
|
$
|
19,803
|
|
|
$
|
14,581
|
|
Stock compensation
(1)
|
|
|
(771)
|
|
|
|
(1,364)
|
|
|
|
—
|
|
Inventory and asset
write-downs, lease abandonment and severance
(2)
|
|
|
4,115
|
|
|
|
—
|
|
|
|
—
|
|
Gain on insurance
recovery (3)
|
|
|
(2,572)
|
|
|
|
—
|
|
|
|
—
|
|
Foreign exchange losses
(gains)
|
|
|
761
|
|
|
|
(239)
|
|
|
|
468
|
|
Excluding specific
items
|
|
$
|
15,707
|
|
|
$
|
18,200
|
|
|
$
|
15,049
|
|
|
|
|
|
Net Income
Attributable to Core Laboratories Inc.
|
|
|
Quarter
Ended
|
|
|
December 31,
2024
|
|
September 30,
2024
|
|
December 31,
2023
|
GAAP
reported
|
|
$7,403
|
|
$11,745
|
|
$2,199
|
Stock compensation
(1)
|
|
(617)
|
|
(1,091)
|
|
—
|
Inventory and asset
write-downs, lease abandonment and severance
(2)
|
|
3,292
|
|
—
|
|
—
|
Gain on insurance
recovery (3)
|
|
(2,058)
|
|
—
|
|
—
|
Foreign exchange losses
(gains)
|
|
610
|
|
(191)
|
|
374
|
Reversal of net
deferred tax liabilities and effect of higher (lower) tax
rate (4)
|
|
1,766
|
|
1,351
|
|
6,336
|
Excluding specific
items
|
|
$10,396
|
|
$11,814
|
|
$8,909
|
|
|
|
|
Diluted Earnings Per
Share Attributable to Core Laboratories Inc.
|
|
|
|
Quarter
Ended
|
|
|
Year
ended
|
|
|
|
December 31,
2024
|
|
|
September 30,
2024
|
|
|
December 31,
2023
|
|
|
December 31,
2024
|
|
GAAP
reported
|
|
$
|
0.15
|
|
|
$
|
0.25
|
|
|
$
|
0.05
|
|
|
$
|
0.66
|
|
Stock compensation
(1)
|
|
|
(0.01)
|
|
|
|
(0.02)
|
|
|
|
—
|
|
|
|
0.02
|
|
Inventory and asset
write-downs, lease abandonment
and severance (2)
|
|
|
0.07
|
|
|
|
—
|
|
|
|
—
|
|
|
|
0.11
|
|
Gain on insurance
recovery (3)
|
|
|
(0.04)
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(0.04)
|
|
Foreign exchange losses
(gains)
|
|
|
0.01
|
|
|
|
(0.01)
|
|
|
|
0.01
|
|
|
|
0.02
|
|
Reversal of net
deferred tax liabilities and effect of
higher (lower) tax rate (4)
|
|
|
0.04
|
|
|
|
0.03
|
|
|
|
0.13
|
|
|
|
0.10
|
|
Excluding specific
items
|
|
$
|
0.22
|
|
|
$
|
0.25
|
|
|
$
|
0.19
|
|
|
$
|
0.87
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) The quarters
ended September 30, 2024 and December 31, 2024 include reversals of
stock compensation expense previously recognized
due to a change in probability of performance conditions for
certain executives' share awards. The year ended December 31, 2024
includes
reversals of stock compensation expense previously recognized due
to a change in probability of performance conditions for certain
executives'
share awards and the acceleration of stock compensation expense
associated with employees reaching eligible retirement
age.
|
|
(2) Includes the
write-down of leasehold improvements, right of use assets and/or
other assets and exit costs associated with consolidation of
certain facilities.
|
|
(3) Includes gain on
insurance recovery associated with the fire incident in one of the
Company's U.K. facilities.
|
|
(4) The quarters
ended September 30, 2024 and December 31, 2024, and the year ended
December 31, 2024, includes the effect to reflect tax
expense at a normalized rate of 20%. The quarter ended December 31,
2023 includes the reversal of certain net deferred tax liabilities
which will
not be realized as a result of the Company's redomestication from
the Netherlands to the United States and the effect to reflect tax
expense at a
normalized rate of 20%.
|
|
Segment
Information (In thousands)
(Unaudited)
|
|
|
|
Operating
Income
|
|
|
|
Quarter Ended
December 31, 2024
|
|
|
|
Reservoir
Description
|
|
|
Production
Enhancement
|
|
|
Corporate and
Other
|
|
GAAP
reported
|
|
$
|
16,643
|
|
|
$
|
(2,597)
|
|
|
$
|
128
|
|
Stock compensation
(1)
|
|
|
(489)
|
|
|
|
(282)
|
|
|
|
—
|
|
Inventory and asset
write-downs, lease abandonment and severance
(2)
|
|
|
—
|
|
|
|
4,115
|
|
|
|
—
|
|
Gain on insurance
recovery (3)
|
|
|
(2,572)
|
|
|
|
—
|
|
|
|
—
|
|
Foreign exchange losses
(gains)
|
|
|
549
|
|
|
|
271
|
|
|
|
(59)
|
|
Excluding specific
items
|
|
$
|
14,131
|
|
|
$
|
1,507
|
|
|
$
|
69
|
|
Return on Invested Capital
Return on Invested Capital ("ROIC") is presented based on
management's belief that this non-GAAP measure is useful
information to investors and management when comparing
profitability and the efficiency with which capital has been
employed over time relative to other companies. The Board has
established an internal metric to demonstrate ROIC performance
relative to the oilfield service companies listed as Core's Comp
Group by Bloomberg. ROIC is not a measure of financial performance
under GAAP and should not be considered as an alternative to net
income.
ROIC of 10.3% is defined by Bloomberg as Net Operating Profit
After Tax ("NOPAT") of $40.9 million
divided by Average Total Invested Capital ("Average TIC") of
$397.6 million, where NOPAT is
defined as GAAP net income before non-controlling interest
plus the sum of income tax expense, interest expense, and
pension expense, less pension service cost and tax effect on
income before interest and tax expense for the last four quarters.
Average TIC is defined as the average of beginning and ending
periods' GAAP stockholders' equity, plus the sum of net
long-term debt, lease liabilities, allowance for credit losses, net
of deferred taxes and income taxes payable.
Free Cash Flow
Core uses the non-GAAP financial measure of free cash flow to
evaluate its cash flows and results of operations. Free cash flow
is defined as net cash provided by operating activities (which is
the most directly comparable GAAP measure) less cash paid
for capital expenditures. Management believes that free cash flow
provides useful information to investors regarding the cash
available in the period in excess of Core's needs to fund its
capital expenditures and operating activities. Free cash flow is
not a measure of operating performance under GAAP and should not be
considered in isolation nor construed as an alternative to
operating income, net income, or cash flows from operating,
investing, or financing activities, each as determined in
accordance with GAAP. Free cash does not represent residual cash
available for distribution because Core may have other
non-discretionary expenditures that are not deducted from the
measure. Moreover, since free cash flow is not a measure determined
in accordance with GAAP and thus is susceptible to varying
interpretations and calculations, free cash flow as presented may
not be comparable to similarly titled measures presented by other
companies.
Computation of Free
Cash Flow (In thousands)
(Unaudited)
|
|
|
|
Quarter
Ended
|
|
|
Year
Ended
|
|
|
|
December 31,
2024
|
|
|
December 31,
2024
|
|
Net cash provided by
operating activities
|
|
$
|
20,615
|
|
|
$
|
56,388
|
|
Capital
expenditures
|
|
|
(4,381)
|
|
|
|
(13,028)
|
|
Free cash
flow
|
|
$
|
16,234
|
|
|
$
|
43,360
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/core-lab-reports-fourth-quarter-and-full-year-2024-results-302363701.html
SOURCE Core Laboratories Inc